Application for endorsement from the Society of
Endocrinology and Metabolism of Turkey
6th Annual European Meeting on the Management of Acromegaly
Dates and venue


The meeting is due to take place on the 25th and 26th September 2015 (1.5 days)
The venue will be Hilton Istanbul Bosphorus, Istanbul, Turkey
Meeting programme




The objective of the meeting is to bring together endocrinologists from across Europe to share best
practice and discuss the latest data and developments surrounding the most pertinent topics in the
management of acromegaly
The programme has been independently developed by a Scientific Planning Committee (SPC) during
a meeting held in Munich, Germany in January 2015
The meeting will be held in the English language
The Scientific Planning Committee is comprised specialists who provide scientific and planning
oversight for the overall programme and content. Its members are recognised authorities in the
field of interest:
● Aart Jan van der Lely, MD, PhD, Erasmus Medical Center, Rotterdam, The Netherlands
● Christian J. Strasburger, MD, Charité Universitätsmedizin, Campus Mitte, Berlin, Germany
● Felipe F. Casanueva, MD, PhD, Santiago de Compostela, Spain
● Ezio Ghigo, MD, University of Turin, Italy
Source of sponsorship

Pfizer Ltd. has initiated and sponsored the 6th Annual European Meeting on the Management of
Acromegaly. The SPCis comprised specialists who provide scientific and planning oversight for the
overall program and content. Its members are recognized authorities in the field of endocrinology
and they receive an honorarium from Pfizer Ltd. for this work. The communications of this Expert
Meeting represent the scientific opinions of the individual presenters and may not necessarily
represent the opinions of Pfizer Ltd., or any of its subsidiaries, partners or employees
Further information
o Synergy Medical Communications Limited is an independent provider of high quality educational
programmes designed for Health Care Professionals. The majority of our programmes are sponsored
by the pharmaceutical industry or independent charity groups/medical societies
o For this meeting we have been engaged by Pfizer to provide third party support for the organisation
of the event
o Our activities engage a range of healthcare providers and are usually associated with objectives
directed at a reduction in risk or improvement in clinical outcomes

Should you have any further questions regarding the meeting or require any further information
then please do contact Isaac Bruce (isaacbruce@synergymedical.co.uk)
1